{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:52:34Z","timestamp":1791661954019,"version":"4.3.4"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202103000089"],"award-info":[{"award-number":["202103000089"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019534","name":"Science Fund for Distinguished Young Scholars of Guangxi Province","doi-asserted-by":"publisher","award":["2020B1515020026"],"award-info":[{"award-number":["2020B1515020026"]}],"id":[{"id":"10.13039\/501100019534","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21804025"],"award-info":[{"award-number":["21804025"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.biopha.2022.113577","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T01:04:15Z","timestamp":1660871055000},"page":"113577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPAR\u03b1) and farnesoid X receptor (FXR)"],"prefix":"10.1016","volume":"154","author":[{"given":"Shipeng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishi","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengquan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) \u2013 pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113577_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41580-022-00486-7","article-title":"Transcriptional control of energy metabolism by nuclear receptors","author":"Scholtes","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tem.2019.10.002","article-title":"Immunoregulatory functions of nuclear receptors: mechanisms and therapeutic implications","volume":"31","author":"Zhao","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2022.113577_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101119","article-title":"Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease","volume":"50","author":"Xiao","year":"2021","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12030238","article-title":"Emerging role of nuclear receptors for the treatment of NAFLD and NASH","volume":"12","author":"Welch","year":"2022","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052668","article-title":"Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease","volume":"23","author":"Puengel","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1172\/JCI88893","article-title":"Nutrient-sensing nuclear receptors PPARalpha and FXR control liver energy balance","volume":"127","author":"Preidis","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41401-021-00849-4","article-title":"FXR: structures, biology, and drug development for NASH and fibrosis diseases","volume":"43","author":"Tian","year":"2022","journal-title":"Acta Pharm. Sin."},{"issue":"12","key":"10.1016\/j.biopha.2022.113577_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/apt.17046","article-title":"Review article: vascular effects of PPARs in the context of NASH","volume":"56","author":"Guixe-Muntet","year":"2022","journal-title":"Aliment. Pharm. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2022.113577_bib14","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1194\/jlr.M027433","article-title":"Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis","volume":"53","author":"Li","year":"2012","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00204-013-1188-0","article-title":"Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARalpha and its relevance to hepatotoxicity","volume":"88","author":"Liu","year":"2014","journal-title":"Arch. Toxicol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113577_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","article-title":"Targeting nuclear receptors for the treatment of fatty liver disease","volume":"179","author":"Tanaka","year":"2017","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113577_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107867","article-title":"The pathophysiological function of non-gastrointestinal farnesoid X receptor","volume":"226","author":"Yan","year":"2021","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113577_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109609","article-title":"Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease","volume":"121","author":"Xi","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"11","key":"10.1016\/j.biopha.2022.113577_bib20","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.bcp.2013.08.015","article-title":"Bile acid receptors in non-alcoholic fatty liver disease","volume":"86","author":"Li","year":"2013","journal-title":"Biochem. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPARalpha in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr. Rev."},{"issue":"16","key":"10.1016\/j.biopha.2022.113577_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168969","article-title":"Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPARalpha","volume":"22","author":"Tahri-Joutey","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2022.113577_bib25","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/ijms21062061","article-title":"PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2022.113577_bib26","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"issue":"22","key":"10.1016\/j.biopha.2022.113577_bib27","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/1078-0432.CCR-19-0253","article-title":"Metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors","volume":"25","author":"Aloia","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/db21-0363","article-title":"Hepatic CPT1A facilitates liver\u2013adipose cross talk via induction of FGF21 in mice","volume":"71","author":"Sun","year":"2022","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.biopha.2022.113577_bib29","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1172\/JCI97831","article-title":"Galpha12 ablation exacerbates liver steatosis and obesity by suppressing USP22\/SIRT1-regulated mitochondrial respiration","volume":"128","author":"Kim","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.biopha.2022.113577_bib30","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1172\/JCI97736","article-title":"Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid beta-oxidation","volume":"128","author":"Seok","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib31","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2018.06.031","article-title":"Diet-induced circadian enhancer remodeling synchronizes opposing hepatic lipid metabolic processes","volume":"174","author":"Guan","year":"2018","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2022.113577_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrm4074","article-title":"Transcriptional regulation of hepatic lipogenesis","volume":"16","author":"Wang","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.biopha.2022.113577_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166249","article-title":"SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1","volume":"1867","author":"Zhu","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib34","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cmet.2017.07.004","article-title":"Sweet sixteenth for ChREBP: established roles and future goals","volume":"26","author":"Abdul-Wahed","year":"2017","journal-title":"Cell Metab."},{"issue":"15","key":"10.1016\/j.biopha.2022.113577_bib35","doi-asserted-by":"crossref","first-page":"13214","DOI":"10.1074\/jbc.M110.215467","article-title":"ChREBP mediates glucose repression of peroxisome proliferator-activated receptor alpha expression in pancreatic beta-cells","volume":"286","author":"Boergesen","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/jcp.29890","article-title":"Carbohydrate response element-binding protein regulates lipid metabolism via mTOR complex1 in diabetic nephropathy","volume":"236","author":"Chen","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.apsb.2020.02.005","article-title":"NF-kappa B\/HDAC1\/SREBP1c pathway mediates the inflammation signal in progression of hepatic steatosis","volume":"10","author":"Guo","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"24","key":"10.1016\/j.biopha.2022.113577_bib38","doi-asserted-by":"crossref","first-page":"21466","DOI":"10.1074\/jbc.M110.209973","article-title":"Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha)","volume":"286","author":"Fernandez-Alvarez","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113577_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.fct.2013.04.018","article-title":"Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH) via modulation of PPARalpha and SREBP-1","volume":"58","author":"Ziamajidi","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.biopha.2022.113577_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111956","article-title":"Echinacoside ameliorates alcohol-induced oxidative stress and hepatic steatosis by affecting SREBP1c\/FASN pathway via PPARalpha","volume":"148","author":"Tao","year":"2021","journal-title":"Food Chem. Toxicol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib41","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/MCB.06175-11","article-title":"Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor alpha in mouse liver reveals extensive sharing of binding sites","volume":"32","author":"Boergesen","year":"2012","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib42","article-title":"Identification of a hormone response element that mediates suppression of APOF by LXR and PPARalpha agonists","volume":"1865","author":"Liu","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib43","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.31881","article-title":"Hepatic small ubiquitin-related modifier (SUMO)-specific protease 2 controls systemic metabolism through SUMOylation-dependent regulation of liver-adipose tissue crosstalk","volume":"74","author":"Liu","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A dozen years of discovery: insights into the physiology and pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib46","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.biopha.2022.113577_bib47","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1111\/bph.14383","article-title":"A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway","volume":"175","author":"Bao","year":"2018","journal-title":"Br. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2022.113577_bib48","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"issue":"50","key":"10.1016\/j.biopha.2022.113577_bib49","doi-asserted-by":"crossref","first-page":"47154","DOI":"10.1074\/jbc.M107000200","article-title":"Antagonism of the actions of peroxisome proliferator-activated receptor-alpha by bile acids","volume":"276","author":"Sinal","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib50","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor","volume":"17","author":"Pineda Torra","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib52","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib53","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.26714","article-title":"Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis","volume":"59","author":"Xu","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib54","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41401-022-00880-z","article-title":"Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease","volume":"43","author":"Jiao","year":"2022","journal-title":"Acta Pharm. Sin."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib55","article-title":"Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation","volume":"1867","author":"Lu","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"10","key":"10.1016\/j.biopha.2022.113577_bib56","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"issue":"15","key":"10.1016\/j.biopha.2022.113577_bib57","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1074\/jbc.M808818200","article-title":"Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis","volume":"284","author":"Bhatnagar","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbadis.2017.10.003","article-title":"Farnesoid X receptor: a \"homeostat\" for hepatic nutrient metabolism","volume":"1864","author":"Massafra","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmet.2005.08.010","article-title":"The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes","volume":"2","author":"Wang","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2022.113577_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib63","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.biopha.2022.113577_bib64","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"issue":"30","key":"10.1016\/j.biopha.2022.113577_bib65","doi-asserted-by":"crossref","first-page":"25123","DOI":"10.1074\/jbc.M112.375907","article-title":"Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21","volume":"287","author":"Cyphert","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113577_bib66","doi-asserted-by":"crossref","first-page":"6889533","DOI":"10.1155\/2021\/6889533","article-title":"The role and mechanism of oxidative stress and nuclear receptors in the development of NAFLD","volume":"2021","author":"Hong","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib67","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-0041-1731707","article-title":"Role of FXR in bile acid and metabolic homeostasis in NASH: pathogenetic concepts and therapeutic opportunities","volume":"41","author":"Radun","year":"2021","journal-title":"Semin. Liver Dis."},{"issue":"7","key":"10.1016\/j.biopha.2022.113577_bib68","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.biopha.2022.113577_bib69","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3390\/cells10112806","article-title":"Bile acid receptors and the gut-liver axis in nonalcoholic fatty liver disease","volume":"10","author":"Xue","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib70","doi-asserted-by":"crossref","first-page":"152","DOI":"10.21037\/hbsn.2019.09.03","article-title":"Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease","volume":"9","author":"Li","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib72","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.biopha.2022.113577_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116046","article-title":"Molecular basis of bile acid-FXR-FGF15\/19 signaling axis","volume":"23","author":"Katafuchi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2022.113577_bib74","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1534-5807(02)00154-5","article-title":"Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis","volume":"2","author":"Kerr","year":"2002","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib75","doi-asserted-by":"crossref","first-page":"1949095","DOI":"10.1080\/19490976.2021.1949095","article-title":"Effect of different bile acids on the intestine through enterohepatic circulation based on FXR","volume":"13","author":"Xiang","year":"2021","journal-title":"Gut Microbes"},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib76","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113577_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111616","article-title":"Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism","volume":"549","author":"Zhou","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113577_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111617","article-title":"Fibroblast growth factor 15\/19 expression, regulation, and function: an overview","volume":"548","author":"Guthrie","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113577_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101152","article-title":"FGF19 and FGF21: in NASH we trust","volume":"46","author":"Talukdar","year":"2021","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib80","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00281-022-00935-7","article-title":"Bile acids and their receptors: modulators and therapeutic targets in liver inflammation","volume":"44","author":"Bertolini","year":"2022","journal-title":"Semin. Immunopathol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113577_bib81","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/hep.31651","article-title":"Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology","volume":"73","author":"Kunst","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113577_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110835","article-title":"ASBT(SLC10A2): a promising target for treatment of diseases and drug discovery","volume":"132","author":"Yang","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib83","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.20295","article-title":"Bile acid-induced negative feedback regulation of the human ileal bile acid transporter","volume":"40","author":"Neimark","year":"2004","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.biopha.2022.113577_bib84","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41401-018-0195-3","article-title":"A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters","volume":"40","author":"Ge","year":"2019","journal-title":"Acta Pharm. Sin."},{"issue":"357","key":"10.1016\/j.biopha.2022.113577_bib85","doi-asserted-by":"crossref","first-page":"357ra122","DOI":"10.1126\/scitranslmed.aaf4823","article-title":"Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice","volume":"8","author":"Rao","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib86","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib87","doi-asserted-by":"crossref","first-page":"G597","DOI":"10.1152\/ajpgi.00310.2017","article-title":"Organic solute transporter OSTalpha\/beta is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury","volume":"314","author":"Malinen","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib88","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.29516","article-title":"Organic solute transporter-beta (SLC51B) deficiency in two brothers with congenital diarrhea and features of cholestasis","volume":"68","author":"Sultan","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113577_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107542","article-title":"Novel insights into the organic solute transporter alpha\/beta, OSTalpha\/beta: from the bench to the bedside","volume":"211","author":"Beaudoin","year":"2020","journal-title":"Pharm. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2022.113577_bib90","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/apt.16602","article-title":"Review article: therapeutic aspects of bile acid signalling in the gut-liver axis","volume":"54","author":"Simbrunner","year":"2021","journal-title":"Aliment. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib91","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jhep.2012.03.025","article-title":"Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism","volume":"57","author":"Lan","year":"2012","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib92","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcmgh.2017.11.011","article-title":"Intestinal farnesoid X receptor activation by pharmacologic inhibition of the organic solute transporter alpha-beta","volume":"5","author":"van de Wiel","year":"2018","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib93","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib94","doi-asserted-by":"crossref","first-page":"G798","DOI":"10.1152\/ajpgi.00319.2004","article-title":"Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver","volume":"289","author":"Zollner","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib95","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbamem.2006.10.008","article-title":"Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis","volume":"1768","author":"Slitt","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"14","key":"10.1016\/j.biopha.2022.113577_bib96","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127197","article-title":"NTCP deficiency in mice protects against obesity and hepatosteatosis","volume":"5","author":"Donkers","year":"2019","journal-title":"Jci Insight"},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib97","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hep.29888","article-title":"Na(+)-taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice","volume":"68","author":"Slijepcevic","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib98","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/jhep.2002.31724","article-title":"Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump","volume":"35","author":"Plass","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib99","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/path.5780","article-title":"Disordered farnesoid X receptor signaling is associated with liver carcinogenesis in Abcb11-deficient mice","volume":"255","author":"Wang","year":"2021","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib101","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"23","key":"10.1016\/j.biopha.2022.113577_bib102","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2022.113577_bib103","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.bbalip.2019.05.014","article-title":"Hepatocyte peroxisome proliferator-activated receptor alpha regulates bile acid synthesis and transport","volume":"1864","author":"Xie","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.biopha.2022.113577_bib104","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1038\/ncomms5573","article-title":"PPARalpha-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis","volume":"5","author":"Zhou","year":"2014","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/toxsci\/kfx191","article-title":"Editor's highlight: clofibrate decreases bile acids in livers of male mice by increasing biliary bile acid excretion in a PPARalpha-dependent manner","volume":"160","author":"Zhang","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biopha.2022.113577_bib106","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.taap.2017.11.014","article-title":"Activation of PPARalpha decreases bile acids in livers of female mice while maintaining bile flow and biliary bile acid excretion","volume":"338","author":"Zhang","year":"2018","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.biopha.2022.113577_bib107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.toxlet.2018.10.015","article-title":"Basal PPARalpha inhibits bile acid metabolism adaptation in chronic cholestatic model induced by alpha-naphthylisothiocyanate","volume":"300","author":"Hua","year":"2019","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/toxsci\/kfx237","article-title":"Alteration of bile acid and cholesterol biosynthesis and transport by perfluorononanoic acid (PFNA) in mice","volume":"162","author":"Zhang","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biopha.2022.113577_bib109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jnutbio.2016.09.015","article-title":"PPARalpha protects against trans-fatty-acid-containing diet-induced steatohepatitis","volume":"39","author":"Hu","year":"2017","journal-title":"J. Nutr. Biochem."},{"issue":"7","key":"10.1016\/j.biopha.2022.113577_bib110","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.biopha.2022.113577_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071638","article-title":"Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease","volume":"9","author":"Fougerat","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.biopha.2022.113577_bib112","first-page":"1464","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib113","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fern\u00e1ndez-Miranda","year":"2008","journal-title":"Dig. Liver Dis.: Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/biology11050792","article-title":"PPAR alpha as a metabolic modulator of the liver: role in the pathogenesis of nonalcoholic steatohepatitis (NASH)","volume":"11","author":"Todisco","year":"2022","journal-title":"Biology"},{"issue":"2","key":"10.1016\/j.biopha.2022.113577_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020274","article-title":"Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates","volume":"10","author":"Prikhodko","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib116","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113577_bib117","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib118","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.biopha.2022.113577_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071667","article-title":"Clinically relevant dose of pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), lowers serum triglyceride levels by targeting hepatic PPARalpha in mice","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","volume":"12","author":"Ishibashi","year":"2018","journal-title":"J. Clin. Lipidol."},{"issue":"10","key":"10.1016\/j.biopha.2022.113577_bib121","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113577_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154707","article-title":"Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters","volume":"117","author":"Briand","year":"2021","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.biopha.2022.113577_bib123","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/liv.14888","article-title":"Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis","volume":"41","author":"Perakakis","year":"2021","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib124","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"12","key":"10.1016\/j.biopha.2022.113577_bib125","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib126","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-021-01648-1","article-title":"Chiglitazar: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib127","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fern\u00e1ndez-Miranda","year":"2008","journal-title":"Dig. Liver Dis."},{"issue":"6","key":"10.1016\/j.biopha.2022.113577_bib128","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","article-title":"Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study","volume":"12","author":"Oscarsson","year":"2018","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113577_bib129","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib130","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.biopha.2022.113577_bib131","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2022.113577_bib132","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib133","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2022.113577_bib134","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-physiol-031620-093815","article-title":"Ceramides in metabolism: key lipotoxic players","volume":"83","author":"Chaurasia","year":"2021","journal-title":"Annu. Rev. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatol. Int."},{"issue":"12","key":"10.1016\/j.biopha.2022.113577_bib136","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic acid: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2022.113577_bib137","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"8","key":"10.1016\/j.biopha.2022.113577_bib138","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41587-020-0634-9","article-title":"Focus shifts to antibody cocktails for COVID-19 cytokine storm","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib139","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113577_bib141","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(20)30570-5","article-title":"Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing","volume":"73","author":"Aspinall","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113577_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2019.12.129","article-title":"Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results","volume":"52","author":"Lucas","year":"2020","journal-title":"Dig. Liver Dis."},{"issue":"1","key":"10.1016\/j.biopha.2022.113577_bib143","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"issue":"10215","key":"10.1016\/j.biopha.2022.113577_bib144","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"9\u201310","key":"10.1016\/j.biopha.2022.113577_bib145","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00508-020-01735-5","article-title":"Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease","volume":"133","author":"Traussnigg","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"issue":"3","key":"10.1016\/j.biopha.2022.113577_bib146","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"issue":"7529","key":"10.1016\/j.biopha.2022.113577_bib147","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature13961","article-title":"Nutrient-sensing nuclear receptors coordinate autophagy","volume":"516","author":"Lee","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib148","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040620","article-title":"Transcriptional regulation of hepatic autophagy by nuclear receptors","volume":"11","author":"Kim","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib149","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.172","article-title":"miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice","volume":"8","author":"Rodrigues","year":"2017","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.biopha.2022.113577_bib150","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11605-021-04908-3","article-title":"Gastric bypass increases circulating bile acids and activates hepatic farnesoid X receptor (FXR) but requires intact peroxisome proliferator activator receptor alpha (PPARalpha) signaling to significantly reduce liver fat content","volume":"25","author":"Mazzini","year":"2021","journal-title":"J. Gastrointest. Surg."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222009660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222009660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:45:45Z","timestamp":1791661545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222009660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":150,"alternative-id":["S0753332222009660"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113577","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPAR\u03b1) and farnesoid X receptor (FXR)","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113577"}}